Table 4.
The most enrichment pathways related to tumorgegesis by KEGG
| Pathway ID | Pathway name | Selection Count | Count | Enrichment |
|---|---|---|---|---|
| mmu05219 | Bladder cancer - Mus musculus (mouse) | 22 | 44 | 3.709033 |
| mmu05216 | Thyroid cancer - Mus musculus (mouse) | 17 | 31 | 3.597993 |
| mmu03430 | Mismatch repair - Mus musculus (mouse) | 13 | 23 | 3.030142 |
| mmu05211 | Renal cell carcinoma - Mus musculus (mouse) | 30 | 77 | 2.524291 |
| mmu04520 | Adherens junction - Mus musculus (mouse) | 29 | 79 | 2.035831 |
| mmu04912 | GnRH signaling pathway - Mus musculus (mouse) | 36 | 104 | 1.939698 |
| mmu05214 | Glioma - Mus musculus (mouse) | 27 | 74 | 1.892937 |
| mmu04110 | Cell cycle - Mus musculus (mouse) | 46 | 140 | 1.872654 |
| mmu05215 | Prostate cancer - Mus musculus (mouse) | 31 | 94 | 1.446692 |
| mmu04150 | mTOR signaling pathway - Mus musculus (mouse) | 20 | 56 | 1.429803 |
| mmu05200 | Pathways in cancer - Mus musculus (mouse) | 98 | 345 | 1.369825 |
| mmu05221 | Acute myeloid leukemia - Mus musculus (mouse) | 21 | 61 | 1.309804 |
"SelectionCounts" stands for the Count of the DE genes' entities directly associated with the listed PathwayID;
"Count" stands for the count of the chosen background population genes' entities associated with the listed PathwayID;